The combination of olodaterol with tiotropium in the treatment of chronic obstructive pulmonary disease – according to current recommendations Review article
Article Sidebar
Published:
Sep 30, 2018
Keywords:
chronic obstructive pulmonary disease, tiotropium, olodaterol, GOLD 2018
Main Article Content
Abstract
Chronic obstructive pulmonary disease leads to the degradation of the respiratory system, which is manifested by increasing obturation, dyspnoea and unfavorably prognostic exacerbations. According to GOLD 2018 recommendations, treatment must decrease symptoms and reduce the risk of exacerbations. Most commonly, a combination of a long-acting anticholinergic drug and a drug from the long-acting β-receptor agonist group is now used. Due to the best activity, safety and the possibility of dosing with one inhaler, the combination of tiotropium improving airway patency with olodaterol, β2-agonist, reducing the risk of exacerbations is considered optimal. Efficacy and safety of the combination of both substances in one inhaler confirmed the results of one of the largest trials of drugs used in chronic obstructive pulmonary disease – TOVITO.
Article Details
How to Cite
Boros, P. (2018). The combination of olodaterol with tiotropium in the treatment of chronic obstructive pulmonary disease – according to current recommendations. Medycyna Faktow (J EBM), 11(3(40), 170-173. https://doi.org/10.24292/01.MF.0318.1
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Global Initiative for Chronic Obstructive Lung Disease: Global Strategy for the Diagnosis, Management, and Prevention of COPD. 2018.
2. Hurst J.R., Vestbo J., Anzueto A. et al.: Susceptibility to exacerbation in chronic obstructive pulmonary disease. N. Engl. J. Med. 2010; 363(12): 1128-1138.
3. Han M.K., Quibrera P.M., Carretta E.E. et al.: Frequency of exacerbations in patients with chronic obstructive pulmonary disease: an analysis of the SPIROMICS cohort. Lancet Respir. Med. 2017; 5(8): 619-626.
4. Miravitlles M., Anzueto A.: A new two-step algorithm for the treatment of COPD. Eur. Respir. J. 2017; 49(2): 1602200.
5. Calzetta L., Rogliani P., Matera M.G., Cazzola M.: A Systematic Review With Meta-Analysis of Dual Bronchodilation With LAMA/LABA for the Treatment of Stable COPD. Chest 2016; 149(5): 1181-1196.
6. Beeh K.M., Derom E., Echave-Sustaeta J. et al.: The lung function profile of once-daily tiotropium and olodaterol via Respimat(®) is superior to that of twice-daily salmeterol and fluticasone propionate via Accuhaler(®) (ENERGITO(®) study). Int. J. Chron. Obstruct. Pulmon. Dis. 2016; 11: 193-205.
7. Halpin D.M.G.: The Role of Tiotropium+Olodaterol Dual Bronchodilator Therapy in the Management of Chronic Obstructive Pulmonary Disease. Tuberc. Respir. Dis. (Seoul) 2018; 81(1): 13-18.
8. Tashkin D.P., Celli B., Senn S. et al.: A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N. Engl. J. Med. 2008; 359(15): 1543-1554.
9. Vogelmeier C., Fabbri L.M., Rabe K.F. et al.: Effect of tiotropium vs. salmeterol on exacerbations: GOLD II and maintenance therapy naive patients. Respir. Med. 2013; 107(1): 75-83.
10. Wedzicha J.A., Calverley P.M., Seemungal T.A. et al.: The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/ fluticasone propionate or tiotropium bromide. Am. J. Respir. Crit. Care Med. 2008; 177(1): 19-26.
11. Deeks E.D.: Olodaterol: a review of its use in chronic obstructive pulmonary disease. Drugs 2015; 75(6): 665-673.
12. Roskell N.S., Anzueto A., Hamilton A. et al.: Once-daily long-acting beta-agonists for chronic obstructive pulmonary disease: an indirect comparison of olodaterol and indacaterol. Int. J. Chron. Obstruct. Pulmon. Dis. 2014; 9: 813-824.
13. Beeh K.M., Westerman J., Kirsten A.M. et al.: The 24-h lung-function profile of once-daily tiotropium and olodaterol fixed-dose combination in chronic obstructive pulmonary disease. Pulm. Pharmacol. Ther. 2015; 32: 53-59.
14. Casanova C., Cote C., de Torres J.P. et al.: Inspiratory-to-total lung capacity ratio predicts mortality in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2005; 171(6): 591-597.
15. Buhl R., Maltais F., Abrahams R. et al.: Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2-4). Eur. Respir. J. 2015; 45(4): 969-979.
16. Singh D., Ferguson G.T., Bolitschek J. et al.: Tiotropium + olodaterol shows clinically meaningful improvements in quality of life. Respir. Med. 2015; 109(10): 1312-1319.
17. Calverley P.M.A., Anzueto A.R., Carter K. et al.: Tiotropium and olodaterol in the prevention of chronic obstructive pulmonary disease exacerbations (DYNAGITO): a double-blind, randomised, parallel-group, active-controlled trial. Lancet Respir. Med. 2018; 6(5): 337-344.
18. Dalby R.N., Eicher J., Zierenberg B.: Development of Respimat(®) Soft Mist Inhaler and its clinical utility in respiratory disorders. Med. Devices (Auckl) 2011; 4: 145-155.
19. Dhand R.: Aerosol plumes: slow and steady wins the race. J. Aerosol Med. 2005; 18(3): 261-263.
20. Feldman G.J., Sousa A.R., Lipson D.A. et al.: Comparative Efficacy of Once-Daily Umeclidinium/Vilanterol and Tiotropium/Olodaterol Therapy in Symptomatic Chronic Obstructive Pulmonary Disease: A Randomized Study. Adv. Ther. 2017; 34(11): 2518-2533.
2. Hurst J.R., Vestbo J., Anzueto A. et al.: Susceptibility to exacerbation in chronic obstructive pulmonary disease. N. Engl. J. Med. 2010; 363(12): 1128-1138.
3. Han M.K., Quibrera P.M., Carretta E.E. et al.: Frequency of exacerbations in patients with chronic obstructive pulmonary disease: an analysis of the SPIROMICS cohort. Lancet Respir. Med. 2017; 5(8): 619-626.
4. Miravitlles M., Anzueto A.: A new two-step algorithm for the treatment of COPD. Eur. Respir. J. 2017; 49(2): 1602200.
5. Calzetta L., Rogliani P., Matera M.G., Cazzola M.: A Systematic Review With Meta-Analysis of Dual Bronchodilation With LAMA/LABA for the Treatment of Stable COPD. Chest 2016; 149(5): 1181-1196.
6. Beeh K.M., Derom E., Echave-Sustaeta J. et al.: The lung function profile of once-daily tiotropium and olodaterol via Respimat(®) is superior to that of twice-daily salmeterol and fluticasone propionate via Accuhaler(®) (ENERGITO(®) study). Int. J. Chron. Obstruct. Pulmon. Dis. 2016; 11: 193-205.
7. Halpin D.M.G.: The Role of Tiotropium+Olodaterol Dual Bronchodilator Therapy in the Management of Chronic Obstructive Pulmonary Disease. Tuberc. Respir. Dis. (Seoul) 2018; 81(1): 13-18.
8. Tashkin D.P., Celli B., Senn S. et al.: A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N. Engl. J. Med. 2008; 359(15): 1543-1554.
9. Vogelmeier C., Fabbri L.M., Rabe K.F. et al.: Effect of tiotropium vs. salmeterol on exacerbations: GOLD II and maintenance therapy naive patients. Respir. Med. 2013; 107(1): 75-83.
10. Wedzicha J.A., Calverley P.M., Seemungal T.A. et al.: The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/ fluticasone propionate or tiotropium bromide. Am. J. Respir. Crit. Care Med. 2008; 177(1): 19-26.
11. Deeks E.D.: Olodaterol: a review of its use in chronic obstructive pulmonary disease. Drugs 2015; 75(6): 665-673.
12. Roskell N.S., Anzueto A., Hamilton A. et al.: Once-daily long-acting beta-agonists for chronic obstructive pulmonary disease: an indirect comparison of olodaterol and indacaterol. Int. J. Chron. Obstruct. Pulmon. Dis. 2014; 9: 813-824.
13. Beeh K.M., Westerman J., Kirsten A.M. et al.: The 24-h lung-function profile of once-daily tiotropium and olodaterol fixed-dose combination in chronic obstructive pulmonary disease. Pulm. Pharmacol. Ther. 2015; 32: 53-59.
14. Casanova C., Cote C., de Torres J.P. et al.: Inspiratory-to-total lung capacity ratio predicts mortality in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2005; 171(6): 591-597.
15. Buhl R., Maltais F., Abrahams R. et al.: Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2-4). Eur. Respir. J. 2015; 45(4): 969-979.
16. Singh D., Ferguson G.T., Bolitschek J. et al.: Tiotropium + olodaterol shows clinically meaningful improvements in quality of life. Respir. Med. 2015; 109(10): 1312-1319.
17. Calverley P.M.A., Anzueto A.R., Carter K. et al.: Tiotropium and olodaterol in the prevention of chronic obstructive pulmonary disease exacerbations (DYNAGITO): a double-blind, randomised, parallel-group, active-controlled trial. Lancet Respir. Med. 2018; 6(5): 337-344.
18. Dalby R.N., Eicher J., Zierenberg B.: Development of Respimat(®) Soft Mist Inhaler and its clinical utility in respiratory disorders. Med. Devices (Auckl) 2011; 4: 145-155.
19. Dhand R.: Aerosol plumes: slow and steady wins the race. J. Aerosol Med. 2005; 18(3): 261-263.
20. Feldman G.J., Sousa A.R., Lipson D.A. et al.: Comparative Efficacy of Once-Daily Umeclidinium/Vilanterol and Tiotropium/Olodaterol Therapy in Symptomatic Chronic Obstructive Pulmonary Disease: A Randomized Study. Adv. Ther. 2017; 34(11): 2518-2533.